Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 7:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8 Clear all

Completed Phase 2 Interventional Results available

Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides

NCT03695471

View directory record Official record

Conditions: Mycosis Fungoides, Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVA2 Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v8
Interventions: Pembrolizumab; Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older

Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Jacksonville, Florida

Source: ClinicalTrials.gov public record

Updated Aug 28, 2025 · Synced May 21, 2026, 7:20 PM EDT

Active, not recruiting Phase 1 Interventional

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome

NCT04652960

View directory record Official record

Conditions: Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Duvelisib, Nivolumab, Positron Emission Tomography, Punch Biopsy; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older

Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 17
States / cities: Phoenix, Arizona • Aurora, Colorado • Coral Gables, Florida + 12 more

Source: ClinicalTrials.gov public record

Updated May 12, 2026 · Synced May 21, 2026, 7:20 PM EDT

Recruiting No phase listed Observational

A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab

NCT07003100

View directory record Official record

Conditions: Recurrent Mycosis Fungoides, Recurrent Sezary Syndrome, Refractory Mycosis Fungoides, Refractory Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
Interventions: Non-Interventional Study; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older

Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 10
States / cities: Duarte, California • Palo Alto, California • Tampa, Florida + 7 more

Source: ClinicalTrials.gov public record

Updated Sep 8, 2025 · Synced May 21, 2026, 7:20 PM EDT

Terminated Phase 1Phase 2 Interventional Results available

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

NCT04541017

View directory record Official record

Conditions: Mycosis Fungoides, Recurrent Mycosis Fungoides, Recurrent Mycosis Fungoides and Sezary Syndrome, Recurrent Sezary Syndrome, Refractory Mycosis Fungoides, Refractory Mycosis Fungoides and Sezary Syndrome, Refractory Sezary Syndrome, Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Magrolimab, Mogamulizumab, Positron Emission Tomography, Punch Biopsy; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older

Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 18
States / cities: Duarte, California • Los Angeles, California • Palo Alto, California + 12 more

Source: ClinicalTrials.gov public record

Updated Oct 15, 2025 · Synced May 21, 2026, 7:20 PM EDT